MeiraGTx Holdings plc filed a current report on September 23, 2026, disclosing the appointment of Alan M. Sebulsky as a Class I director to its Board of Directors, effective September 23, 2026.
Key Highlights
- New director appointed: Alan M. Sebulsky was appointed to the MeiraGTx Holdings plc Board of Directors as a Class I director, effective September 23, 2026.
- Term length: His term expires at the Company's 2028 annual meeting of shareholders, when Class I directors are up for re-election.
- Committee assignment: Mr. Sebulsky has been appointed to serve as a member of the Science and Technology Committee.
- Current role: Mr. Sebulsky has served as Managing Member of Apothecary Capital LLC since its reestablishment in April 2026.
- Prior experience: He previously served as a Partner and Portfolio Manager at Adage Capital Management, LP from July 2012 to April 2026, managing a biopharmaceutical portfolio.
- No related party transactions: The filing states there are no related party transactions between the Company and Mr. Sebulsky.
MeiraGTx Adds Biopharmaceutical Investment Veteran to Its Board
According to the filing, the Board of Directors of MeiraGTx Holdings plc (NASDAQ:MGTX), acting upon the recommendation of its Nominating and Corporate Governance Committee, appointed Alan M. Sebulsky as a Class I director on September 22, 2026, with the appointment taking effect on September 23, 2026. The filing notes that Mr. Sebulsky was recommended as a potential candidate by the Company's senior management, and that he was not selected pursuant to any arrangement or understanding between him and any other person.
The filing describes Mr. Sebulsky's professional background as spanning several decades in investment management focused on healthcare and biopharmaceuticals. In addition to his current role as Managing Member of Apothecary Capital LLC, which was reestablished in April 2026, he previously held the position of Partner and Portfolio Manager at Adage Capital Management, LP from July 2012 to April 2026. Prior to that, he served as a Portfolio Manager at BBT Capital Management Advisory LLC from April 2003 to March 2012, alongside his role as Managing Partner of Apothecary Capital LLC over the same period. From 1994 to 2002, he held various positions including Managing Director at Lincoln Capital Management, where the filing states he was responsible for investments in the healthcare industry.
The filing also discloses that Mr. Sebulsky currently serves on the board of directors of Parabilis Medicines, Inc, and previously served on the boards of Jazz Pharmaceuticals PLC and Arrow International, Inc. He holds a B.B.A. in finance and economics and an M.S. in finance from the University of Wisconsin, Madison, according to the filing. The filing states he will be eligible to receive compensation pursuant to the Company's Non-Employee Director Compensation Program and is expected to enter into the Company's standard form of indemnification agreement for directors and officers.
What Was Disclosed
MeiraGTx Holdings plc disclosed the appointment of Alan M. Sebulsky as a Class I director effective September 23, 2026, his assignment to the Science and Technology Committee, his professional background, compensation eligibility, and the absence of any related party transactions.



Please wait processing your request...